Histone deacetylase inhibition in the treatment of heart disease

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Recent work has demonstrated the importance of chromatin remodeling, especially histone acetylation, in the control of gene expression in the heart. Studies in preclinical models suggest that inhibition of histone deacetylase (HDAC) activity - using compounds that show promise in ongoing oncology trials - blunts pathologic growth of cardiac myocytes. Indeed, small-molecule inhibitors of HDACs are members of an evolving class of pharmacologic agents in development for the treatment of several diseases. If proved effective in the treatment of heart disease, HDAC inhibitors could have a significant impact on public health, as cardiovascular disease remains the leading cause of death in the US. This paper reviews understanding of the mechanisms of action of HDAC inhibitors in the heart and summarizes emerging data regarding their effects on disease-related cardiac remodeling and function.

Original languageEnglish (US)
Pages (from-to)53-67
Number of pages15
JournalExpert Opinion on Drug Safety
Issue number1
StatePublished - Jan 2008


  • Cardiac hypertrophy
  • Fibrosis
  • Heart failure
  • Histone deacetylases
  • Remodeling

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Histone deacetylase inhibition in the treatment of heart disease'. Together they form a unique fingerprint.

Cite this